A Comprehensive Review on Fluconazole: Clinical Efficacy, Pharmacokinetics, and Newly Emerging Challenges of Resistance

Nikita Varfa 
Charak Institute of Pharmacy, Mandleshwar, Khargone, Madhya Pradesh, India  
Correspondence to: Nikita Varfa, nikitavarfa@gmail.com

DOI: https://doi.org/10.70389/PJS.100276

Additional information

• Ethical approval: N/a
• Consent: N/a
• Funding: No industry funding
• Conflicts of interest: N/a
• Author contribution: Nikita Varfa – Conceptualization, Writing – original draft, review and editing
• Guarantor: Nikita Varfa
• Provenance and peer-review: Unsolicited and externally peer-reviewed
• Data availability statement: N/a

Keywords: Antifungal stewardship, Candida species, ERG11 mutations, Fluconazole, Invasive fungal infections.

Peer Review
Received: 11 February 2026
Last revised: 4 May 2026
Accepted: 4 May 2026
Version accepted: 3
Published: 11 May 2026

Plain Language Summary Infographic

Introduction

Fungal infections, also known as mycoses, are eitherare either superficial or invasive into vital organs, such as the lungs, brain, and blood, and, in most cases, cause death. The burden of invasive fungal diseases worldwide is high, with an estimated 6.75 million cases and about 3.8 million deaths every year, with many of these directly related to fungal infection. Due to the increase in the number of immunocompromised, such as cancer, diabetes, or receiving immunosuppressive treatment, there has been an increased need for systemic antifungal therapy butstill, mortality rates remain high, with some invasive fungal infections having mortality rates exceeding 40%–70%, based on the pathogen and patient population.¹

The surveillance data show that the incidence of yeast fungemia and other invasive fungal diseases is slightly rising and that the remaining diseases are not decreasing, with older patients having a higher incidence.² The prevalence of invasive fungal infections among critically ill patients is pooled at the levels of 5% with Candida and Aspergillus species, leading to substantial prevalence and mortality rates, despite the improvements in diagnostics and effective treatment of these infections. These results indicate a dire need to come up with better prevention, early diagnosis, and management strategies to curb the worldwide health burden of invasive fungal diseases.¹

First-generation triazole Fluconazole (approved 1990) was the first oral agent to be used as treatment of fungi; it was an effective agent due to its high oral bioavailability (>90%), low protein affinity, and wide tissue distribution, including approximately 80% cerebral penetration into cerebral spinal fluid (CSF) in cryptococcal meningitis.^3,4 Its action is selective inhibition of lanosterol 14-alpha-demethylase that impairs the ergosterol synthesis needed in cell membrane integrity of fungi, causing fungal death with the least toxicity to the human cell. Fluconazole is mainly excreted by the kidneys, so the dosage has to be increased in patients with renal failure or under dialysis. Its half-life is long, which enables easy dosages to be administered.⁵

Nevertheless, the clinical utility of fluconazole is now facing an increasing threat due to emerging antifungal resistance, particularly in Candida parapsilosis and Cryptococcus neoformans, which is frequently associated with genetic mutation, including ERG11 gene mutation and aneuploidy of chromosomes, which makes the treatment of the disease more difficult.⁶ Development of resistance is especially troublesome with cryptococcal meningitis, where monotherapy of fluconazole demonstrates poor results, owing to the development of dynamic resistance, with only a minimal proportion of patients achieving sterility of their CSF, even with high doses (1200 mg/day), and some resistant subpopulations remaining.⁵ To address these problems, antifungal stewardship, maximized dose regimens, combination therapy, and the investigation of novel antifungal agents such as posaconazole and rezafungin, which are active against resistant strains and have the potential to enhance the clinical outcome, are essential.⁶

Methods

The electronic databases, such as PubMed, Scopus, and Google Scholar, were used to find pertinent material published between 2000 and 2025 for this narrative review. Using Boolean operators (AND, OR) in conjunction with terms like “fluconazole,” “antifungal resistance,” “pharmacokinetics,” “candidiasis,” and “cryptococcosis,” a thorough search strategy was implemented to narrow down the search results. Based on predetermined inclusion and exclusion criteria, studies were chosen. Peer-reviewed publications, clinical trials, systematic reviews, and meta-analyses that concentrated on the pharmacological characteristics, clinical effectiveness, and resistance mechanisms of fluconazole were among the inclusion criteria.

Studies offering molecular insights into antifungal resistance were also considered. Non-English publications, duplicate records, conference abstracts without complete data, and research without full-text access were among the exclusion criteria. To guarantee therapeutic relevance, pertinent clinical practice guidelines from groups like the IDSA (Infectious Diseases Society of America) and the ECMM (European Confederation of Medical Mycology) were also incorporated.^7,8 To ascertain eligibility, all identified papers were first screened using titles and abstracts, and then their entire texts were examined. To guarantee the inclusion of current evidence, preference was given to recent, high-quality, and clinically significant studies.

Pharmacokinetics of Fluconazole

Fluconazole has predictable, linear pharmacokinetics, excellent oral bioavailability, wide tissue penetration (including CNS), predominantly renal elimination, and a long halflife enabling oncedaily dosing.

Core Pharmacokinetic Properties

1. Absorption & Bioavailability: Oral bioavailability >90%; IV and oral exposure are essentially equivalent, and food or gastric pH has minimal impact.⁹
2. Distribution: Volume of distribution ~0.7–0.75 L/kg, approximating total body water, with low plasma protein binding (~11%–12%).¹⁰
3. CSF levels reach ~50%–90% (often ~80%) of simultaneous plasma concentrations, supporting use in meningitis.¹¹
4. High concentrations in urine and skin; urine levels may be 10–20× plasma.¹²
5. Elimination & Metabolism: Metabolically stable; 60%–80% excreted unchanged in urine, ~70%–80% via renal clearance.¹³
6. Halflife ≈ 27–31 h in adults, allowing oncedaily dosing and two- to threefold accumulation at steady state by Day 5–7; loading dose (≈12 mg/kg) shortens time to target levels.¹³
7. Halflife markedly prolonged in renal failure (up to ~72–96h), requiring dose reduction; dialysis and CRRT efficiently clear the drug and may need supplemental or higher doses (Table 1).

Table 1: Pharmacokinetics in special populations.
Population/Condition	Key PK Change	Dosing Implication	Citations
Renal impairment/dialysis	clearance, half-life, RRT adds extracorporeal clearance	Reduce dose, supplement or increase with CRRT	14,15
Critically ill (ICU)	High interpatient variability, effects of ARC, CRRT, and weight	Higher, often weight-based doses, consider TDM	16,17
Obese/morbidly obese	clearance and Vd, risk of underexposure	Loading 12 mg/kg, maintenance 6 mg/kg/day	18–20
Burn/septic patients	Shorter half-life, altered Vd, and clearance	Higher daily doses may be needed	21,22
Children	Shorter half-life vs. adults	Higher mg/kg dosing	11

Drug–Drug Interactions

Fluconazole inhibits CYP2C9, CYP2C19, and CYP3A4 (Figure 1), causing clinically relevant interactions with warfarin, phenytoin, tacrolimus, and other narrowtherapeuticindex drugs.²³

Mechanism of Action

The triazole antifungal drug fluconazole works by specifically blocking the fungal cytochrome P450 enzyme lanosterol 14-α-demethylase, which is produced by the ERG11 gene. The formation of ergosterol, a crucial structural element of the fungal cell membrane, depends on the demethylation of lanosterol, which is catalyzed by this enzyme. Toxic 14-methyl sterol intermediates build up, and ergosterol is depleted when lanosterol 14-α-demethylase is inhibited. These changes impede the function of membrane–associated proteins and enzymes, compromise membrane integrity, and increase membrane permeability, all of which eventually prevent fungal growth.

Although fungicidal effects may occur at greater concentrations against susceptible species like Candida albicans, fluconazole primarily demonstrates fungistatic activity. These effects have been linked to increased production of reactive oxygen species (ROS), intracellular metacaspases, and mitochondrial malfunction, all of which contribute to fungal cell death. Crucially, fluconazole exhibits selective toxicity because it has a greater affinity for fungal cytochrome P450 enzymes than its mammalian counterparts, which reduces its effects on host cells (Table 2).²⁴

Table 2: Significant pharmacological characteristics, clinical uses, and resistance issues of fluconazole.
Parameter	Key Details	Clinical Relevance
Drug class	First-generation bis-triazole antifungal	Widely used systemic azole agent
Year of approval	1990 (FDA)	Extensive clinical experience
Mechanism of action	Inhibition of lanosterol 14-α-demethylase (ERG11), leading to inhibition of ergosterol biosynthesis	Disrupts fungal cell membrane integrity
Antifungal activity	Primarily fungistatic; fungicidal at higher doses (e.g., Candida albicans)	Dose-dependent therapeutic efficacy
Oral bioavailability	>90%	Reliable and effective oral therapy
Protein binding	Low (~11%–12%)	High free drug fraction enhances activity
Tissue distribution	Extensive; CSF penetration ~80% of plasma levels	Effective in central nervous system infections
Elimination	Primarily renal (excreted unchanged)	Dose adjustment required in renal impairment
Major clinical uses	Candidiasis, cryptococcal meningitis (maintenance), prophylaxis in immunocompromised patients	Broad therapeutic applicability
Advantages	Good tolerability, oral and intravenous formulations, long half-life	Improved patient compliance
Limitations	Fungistatic activity and lack of efficacy against molds	Restricted antifungal spectrum
Key resistance mechanisms	ERG11 mutations, efflux pump overexpression (CDR1, MDR1), biofilm formation, heteroresistance	Reduced susceptibility and potential treatment failure

Fluconazole Resistance Mechanisms in Fungi

Fluconazole resistance is a growing problem in Candida spp. and Cryptococcus neoformans, driven by several welldefined molecular and cellular adaptations.

Main Resistance Mechanisms

• Target alteration (ERG11/UPC2 changes): Point mutations in ERG11 (lanosterol 14αdemethylase) lower fluconazole binding; gainoffunction mutations in UPC2 increase ERG11 expression, both reducing drug efficacy, widely shown in C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, and C. auris.²⁵
• Efflux pump overexpression: Upregulation of ABC transporters (CDR1, CDR2, SNQ2) and MFS transporters (MDR1) actively exports fluconazole. These are often driven by gainoffunction mutations in transcription factors such as TAC1, TAC1B, MRR1, PDR1.²⁶
• Biofilm-associated resistance: Biofilms on mucosal surfaces and devices show higher fluconazole MICs; efflux pump genes (CDR1, CDR2, MDR1) are upregulated, and the extracellular matrix (e.g., β-1, 3-glucans) limits drug penetration and can bind azoles, promoting multidrug tolerance.²⁷

Fluconazole Resistance & Heteroresistance in Cryptococcus

• Heteroresistance: In C. neoformans, small subpopulations grow at high fluconazole levels; this is linked to chromosomal disomy of chromosome 1 with overexpression of ERG11 and the ABC efflux pump AFR1, allowing survival above the MIC and reversible adaptation once drug pressure is removed.²⁸
• Chromosomal aneuploidy/gene dosage: Amplification of chromosomes carrying resistance genes (e.g., Chr1 with ERG11, AFR1) increases gene dosage and fluconazole resistance in Cryptococcus and contributes to stepwise resistance in Candida via segmental aneuploidies and gene amplification.²⁹
• Stress-response and cellular adaptations: Fluconazole exposure can select changes in sterol/sphingolipid pathways, mitochondrial function, and oxidativestress handling, increasing tolerance and allowing accumulation of ERG11/efflux alterations over time.³⁰

Clinical Efficacy of Fluconazole

Fluconazole is a bis-triazole antifungal agent that has good pharmacokinetic properties, such as high-water solubility, metabolic stability, and good tissue penetration; therefore, it can be used to treat various fungal infections, including oropharyngeal, esophageal, and disseminated candidiasis, with clinical response rates ranging between 50%–90%. It also works well in cryptococcal meningitis, especially combined with amphotericin B therapy, with such a combination giving equal levels of clinical response and relapse prevention.³¹ Fluconazole has been frequently used as prophylaxis in immunocompromised patients receiving chemotherapy or bone marrow transplantation, in lowering the frequency of oral fungal infections and invasive candidiasis, and in low-dose regimens, similar effectiveness and safety have been observed as in higher doses.³² Fungistatic, not fungicidal, but easy to administer in either oral or intravenous form, fluconazole is typically better tolerated than other antifungals.

Once-daily dosing is convenient, and it is being used in Candida glabrata and Cryptococcus neoformans, but resistance is a problem in Candida glabrata. Its merits are high patient compliance, mild side effects, and a wide range of usability in both prophylaxis and treatment; however, its demerits are that it may cause relapses in immunocompromised patients, it is potentially hepatotoxic, and it exhibits less effectiveness against resistant strains, forcing close clinical usage and observation.³³ In general, fluconazole has become an important antifungal agent with proven clinical efficacy, especially in the treatment of candidiasis and cryptococcosis (Figure 2), but the use of these drugs should be adjusted to the susceptibility patterns and patient risk factors in order to maximize the effect.³⁴

Safety Profile and Adverse Effects

The following are the common adverse drug reactions with fluconazole: gastrointestinal, skin reactions, xerosis, alopecia, and fatigue, with a number of patients experiencing mild to moderate effects, which occasionally necessitate a reduction in dose or discontinuation, particularly in long-term use. Hepatotoxicity is another significant issue, as there have been increased liver enzymes in both adults and children, though the majority of cases will heal fully when monitored and dose-regulated; drug interactions may result in more liver toxicity and should be considered carefully. Fluconazole, which is commonly used for chronic fungal infections, has a greater rate of adverse effects, especially fatigue and skin problems, and approximately two out of every three infected individuals may require therapeutic modification.

Serious but infrequent adverse events are neurotoxicity and cardiac conditions, such as changes in the QT interval and systemic reactions, which may be fatal and merit vigilance in treatment. Fluconazole is more tolerable than other antifungals and has a reduced percentage of therapy discontinuation because of adverse effects; however, it is important to monitor liver, kidney, and cardiovascular functions, particularly in high-risk groups and when administered over a long period. All in all, the safety of fluconazole is positive and needs continuous clinical observation to address hepatotoxicity, drug interactions, and infrequent severe adverse events to promote safe and effective use.³⁵

Emerging Challenges of Fluconazole Resistance

Fluconazole resistance is a growing issue worldwide, especially among Candida species, including Candida albicans, Candida glabrata, and Candida parapsilosis, whose resistance mechanisms encompass mutations in ergosterol biosynthesis pathways (e.g. ERG11), overexpression of efflux pumps, and biofilm formation, all of which contribute to decreased drug susceptibility.³⁶ Candida parapsilosis has been demonstrated to have significant resistance to fluconazole in the case of hospital outbreaks that are highly fatal, usually due to particular gene mutations, such as Y132F, and the development of resistance can occur even in patients who are new to azoles.³⁷

The heteroresistance mechanism of Cryptococcus neoformans is a survival of subpopulations at increased drug levels, which is frequently caused by chromosomal disomy, overexpressing resistance genes, including ERG11 and AFR1, and making them more difficult to treat and linked to worse clinical outcomes.³⁸ The long-term and prophylactic treatment of fluconazole in immunocompromised patients facilitates the emergence of resistant strains due to the selective pressure caused by antifungal use, which causes the necessity of antifungal stewardship and the exclusion of alternative therapy. Surveillance evidence suggests that there is a gradual yet consistent growth in isolated cases of fluconazole-resistance around the globe, where regional disparities and the development of multidrug resistance represent a huge treatment challenge. On the whole, to control the spread of resistance to fluconazole, it is essential to comprehend the molecular resistance mechanism and track epidemiological trends to make effective clinical decisions.³⁷

Molecular Mechanisms of Resistance

Molecular processes of changing the targets of drugs, increasing the efflux of the drug, and modifying cell components are the main mechanisms of resistance to fluconazole among the most common pathogenic fungi. The major mutations are observed in the gene (ERG11) of the ergosterol-biosynthesis pathway, along with its regulator (UPC2), which decreases the ability to bind fluconazole and its activity.³⁹ Active expression of efflux pump genes (CDR1, CDR2, and MDR1), usually controlled by transcription factors (TAC1 and PDR1), actively extrudes fluconazole out of fungal cells and plays a role in resistance, particularly in Candida albicans and Candida glabrata.⁴⁰

Such a rapid adaptive response has been found to be aneuploidy, the acquisition of an additional chromosome that has resistance genes, which has increased fluconazole resistance by increasing the gene dosage.⁴¹ Other mechanisms are changes in the sphingolipid composition, which influence the membrane properties and drug susceptibility, and biofilm formation, which offers a sheltered environment against antifungals.³⁶ All these molecular adaptations demonstrate that resistance to fluconazole is a complicated issue and requires specific strategies to address it in different Candida types and other future pathogens such as C. auris.⁴²

Strategies to Overcome Fluconazole Resistance

The combinations of antifungal therapy, adjuvant agent use, derivatives of fluconazole, focusing on other ergosterol pathway sites, and antifungal stewardship programs are the strategies to overcome resistance to fluconazole. Synergies between combination therapies have been reported; for example, between fluconazole and curcumin nanosuspensions, iron chelators like deferasirox, and disrupting biofilms, thus regaining fluconazole activity against resistant Candida strains.⁴³ Delivery systems that utilize nanoparticles also cause a reduction in effective doses of fluconazole and resistance reversal by enhancing the bioavailability of drugs and by targeting a variety of resistance pathways.⁴⁴

Novel molecular pathways can be targeted to re-sensitize resistant strains to fluconazole, including the ATP-dependent unfoldase ClpX that is found in Cryptococcus neoformans, which provides new therapeutic opportunities.⁴⁵ The new antifungal agents that have different mechanisms of action, such as anti–ergsterol and anti-b-glucan biosynthesis, are under development in an effort to overcome resistance and toxicity problems of the available medications.³⁷ Lastly, antifungal stewardship measures are essential to reduce unwarranted use of fluconazole as well as to decrease the selective pressure and delay the occurrence of resistance, and natural substances, such as flavonoids and freshwater mussel extracts, have potential as adjuvants to increase fluconazole susceptibility and decrease fungal virulence.⁴⁶

Recent Advances and Future Perspectives

Recent developments in the field of overcoming fluconazole resistance are oriented toward new research directions, new drug formulations, and use of personalized antifungal therapy. The resistance and toxicity of existing antifungal drugs are being countered by exploring new antifungal agents with novel mechanisms, including ergosterol and β-glucan biosynthesis antifungals, among others.²⁴ Nanosuspensions of curcumin and solid lipid nanoparticles that are designed in nanotechnology increase the effect of fluconazole in the treatment of persistent fungal biofilms by increasing solubility, bioavailability, and targeting biofilms.⁴³

The small molecules, such as the 1,4-benzodiazepines, have been found that can restore the fluconazole susceptibility in the resistant strains by enhancing drug efficacy and suppressing fungal virulence factors, and have potential in the systemic infection models.⁴⁷ Individualized antifungal treatment, informed by knowledge of individual resistance mechanisms; for example, mutation in Candida parapsilosis or the involvement of proteins like ClpX in Cryptococcus neoformans, could yield better treatment outcomes by directing drug selection and combinations. All in all, the combination of new formulas, specific therapies, and programs of stewardship is the overall future approach to handling the increasing challenge of fluconazole resistance.⁴⁸

Conclusion

Fluconazole is an antifungal agent, which is considered a cornerstone antifungal agent because of its good pharmacokinetics, high tolerability, and wide clinical applicability. It is especially useful in treating invasive and opportunistic infections caused by fungi, due to its capacity to attain a high bioavailability and reach critical locations, including the central nervous system. Nevertheless, the growing level of resistance among Candida species and Cryptococcus neoformans is an expanding issue. The mechanisms of resistance, such as ERG11 gene mutations, activation of efflux pumps, and adaptive stress responses, influence the efficacy and clinical outcomes of the treatment to a significant extent.

These issues highlight the need to focus on proper dosing approach, therapeutic drug observation in special groups, and the rational application of antifungal agents. The future outlook would be the creation of new fluconazole derivatives, combination therapy, and new drug delivery systems like nanocarriers to increase antifungal efficacy and surmount resistance. Moreover, the concept of individual antifungal treatment, depending on pharmacokinetic–pharmacodynamic principles and pathogen-specific patterns of susceptibility, is prospective to enhance treatment outcomes. Surveillance and further research are needed to maintain the long-term efficacy of fluconazole in clinical practice.

References

1. Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428–e438.
   https://doi.org/10.1016/S1473-3099(23)00692-8
2. Bretagne S, Sitbon K, Desnos-Ollivier M, et al. French Mycoses Study Group. Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF network (2012 to 2018). mBio. 2022;13(3):e0092022.
3. Singh S, Chandra U, Anchan VN, Verma P, Tilak R. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. Br J Dermatol. 2020;183(5):840–846.
   https://doi.org/10.1111/bjd.19146
4. Chitharagi VB, Sem JN, Morubagal RR, et al. Recent trends in the susceptibility pattern of Candida to fluconazole and amphotericin B at a tertiary care center in South India. IP Int J Med Microbiol Trop Dis. 2024;10(1):62–66. https://doi.org/10.18231/j.ijmmtd.2024.011
5. Yang Y, Shang J, Xu S, Wang Z. Dose optimization of fluconazole after initial treatment failure in pulmonary cryptococcosis in an obese patient with type 2 diabetes and cirrhosis: a case report. Infect Drug Resist. 2024;17:4993–5000.
6. Gupta AK, Talukder M, Shemer A, Galili E. Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis. Expert Rev Anti Infect Ther. 2024;22(6):399–412.
   https://doi.org/10.1080/14787210.2024.2362911
7. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. https://doi.org/10.1093/cid/civ933
8. Hoenigl M, Gangneux JP, Segal E, et al. European Confederation
   of Medical Mycology (ECMM). Global guidelines and initiatives from the European Confederation of Medical Mycology to
   improve patient care and research worldwide: new leadership is about working together. Mycoses. 2018;61(11):885–894. https://doi.org/10.1111/myc.12836
9. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993;24(1):10–27.
   https://doi.org/10.2165/00003088-199324010-00002
10. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985;28(5):648–653. https://doi.org/10.1128/AAC.28.5.648
11. Wildfeuer A, Laufen H, Schmalreck AF, Yeates RA, Zimmermann T. Fluconazole: comparison of pharmacokinetics, therapy and in
    vitro susceptibility. Mycoses. 1997;40(7–8):259–265.
    https://doi.org/10.1111/j.1439-0507.1997.tb00230.x
12. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737–779. https://doi.org/10.1007/s15010-017-1042-z
13. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl 3):318–326.
14. Zhang S, Zhang W, Wu T, Qin Y, Pei Q. Optimizing fluconazole dosing in acute renal failure patients undergoing continuous renal replacement therapy: a population pharmacokinetic/pharmacodynamic study. Front Pharmacol. 2025;16:1564070. https://doi.org/10.3389/fphar.2025.1564070
15. Muilwijk EW, de Lange DW, Schouten JA, et al. Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing. Antimicrob Agents Chemother. 2020;64(10):e00984-20.
    https://doi.org/10.1128/AAC.00984-20
16. Vuong M, Elkayal O, Van Daele R, et al. A fluconazole population pharmacokinetics study to improve target attainment in
    critically ill patients. Infection. 2026;54(1):299–313.
    https://doi.org/10.1007/s15010-025-02663-0
17. Van Daele R, Wauters J, Lagrou K, et al. Pharmacokinetic variability and target attainment of fluconazole in critically ill patients. Microorganisms. 2021;9(10):2068. https://doi.org/10.3390/microorganisms9102068
18. Boonstra JM, Märtson AG, Sandaradura I, et al. Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2021;65(3):e01554-20. https://doi.org/10.1128/AAC.01554-20
19. Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2016;60(11):
    6550–6557. https://doi.org/10.1128/AAC.01088-16
20. Chen L, van Rhee KP, Wasmann RE, et al. Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. J Antimicrob Chemother. 2022;77(8):2217–2226.
    https://doi.org/10.1093/jac/dkac160
21. Matsuno VK, Campos EV, Silva Junior EM, et al. Changes in fluconazole pharmacokinetics can impact on antifungal effectiveness in critically ill burn patients: a Pharmacokinetic-Pharmacodynamic (PK/PD) approach. Clinics (Sao Paulo). 2024;79:100491. https://doi.org/10.1016/j.clinsp.2024.100491
22. Pittrow L, Penk A. Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycoses. 1999;42(S2 Suppl 2):
    87–90. https://doi.org/10.1111/j.1439-0507.1999.tb00020.x
23. Lazar JD, Hilligoss DM. The clinical pharmacology of fluconazole. Semin Oncol. 1990;17(3 Suppl 6):14–18.
24. Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–259. https://doi.org/10.2147/IDR.S124918
25. Pandey N, Tripathi M, Gupta MK, Tilak R. Overexpression of efflux pump transporter genes and mutations in ERG11 pave the way to fluconazole resistance in Candida tropicalis: a study from a North India region. J Glob Antimicrob Resist. 2020;22:374–378.
    https://doi.org/10.1016/j.jgar.2020.02.010
26. Mane A, Vidhate P, Kusro C, et al. Molecular mechanisms associated with fluconazole resistance in clinical Candida
    albicans isolates from India. Mycoses. 2016;59(2):93–100. https://doi.org/10.1111/myc.12439
27. Shi C, Liu J, Li W, Zhao Y, Meng L, Xiang M. Expression of fluconazole resistance-associated genes in biofilm from 23 clinical isolates of Candida albicans. Braz J Microbiol. 2019;50(1):
    157–163. https://doi.org/10.1007/s42770-018-0009-2
28. Yang F, Gritsenko V, Lu H, et al. Adaptation to fluconazole via aneuploidy enables cross-adaptation to amphotericin B and flucytosine in Cryptococcus neoformans. Microbiol Spectr. 2021;9(2):e0072321. https://doi.org/10.1128/Spectrum.00723-21
29. Morschhäuser J. The development of fluconazole resistance in Candida albicans—an example of microevolution of a fungal pathogen. J Microbiol. 2016;54(3):192–201. https://doi.org/10.1007/s12275-016-5628-4
30. Cárdenas Parra LY, Rojas Rodríguez AE, Pérez Cárdenas JE, Pérez-Agudelo JM. Molecular evaluation of the mRNA expression of the ERG11, ERG3, CgCDR1, and CgSNQ2 genes linked to fluconazole resistance in Candida glabrata in a Colombian population. J Fungi (Basel). 2024;10(7):509. https://doi.org/10.3390/jof10070509
31. Grant SM, Clissold SP. Fluconazole. a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990;39(6):877–916. https://doi.org/10.2165/00003495-199039060-00006
32. Savary-Kouzehkonan R, Sadeghi K, Rad S, et al. Efficacy of
    low-dose fluconazole for primary prophylaxis of invasive
    Candida infections in patients with acute leukemia: a double-blind randomized clinical trial. Cancer Med. 2025;14.
    https://doi.org/10.1002/cam4.70837
33. Liao T, Lin Y, Huang C, Hwu C, Lin L. Clinical efficacy and safety of fluconazole treatment in patients with Cushing’s syndrome. Ther Adv Endocrinol Metab. 2025;16. https://doi.org/10.1177/20420188251372275
34. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after
    15 years? J Antimicrob Chemother. 2006;57(3):384–410.
    https://doi.org/10.1093/jac/dki473
35. Su T, Li J, Si S, Xin L. Analysis of adverse events induced by fluconazole based on the FAERS database. Expert Opin Drug Saf. 2025;10:1–9. https://doi.org/10.1080/14740338.2025.2490837
36. Czajka KM, Venkataraman K, Brabant-Kirwan D, et al. Molecular mechanisms associated with antifungal resistance in pathogenic Candida species. Cells. 2023;12(22):2655. https://doi.org/10.3390/cells12222655
37. Bartalucci C, Vena A, Giacobbe DR, Bassetti M. Clinical impact of fluconazole-resistant Candida parapsilosis: a narrative review. Future Microbiol. 2025;20(13):903–912. https://doi.org/10.1080/17460913.2025.2544443
38. Moreira IM, Sousa NS, Almeida JD, et al. Fluconazole resistance and heteroresistance in Cryptococcus spp.: mechanisms and implications. Rev Soc Bras Med Trop. 2025;58:e002002025. https://doi.org/10.1590/0037-8682-0328-2024
39. Fan X, Xiao M, Zhang D, et al. Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China. Clin Microbiol Infect. 2019;25(7):885–891. https://doi.org/10.1016/j.cmi.2018.11.007
40. Xia C, Liu R, Zhang S, Shen J, Wang Z. Fluconazole-induced changes in azole resistance and biofilm production in Candida glabrata
    in vitro. Diagn Microbiol Infect Dis. 2025;111(3):116683.
    https://doi.org/10.1016/j.diagmicrobio.2025.116683
41. Bing J, Hu T, Zheng Q, Muñoz JF, Cuomo CA, Huang G. Experimental evolution identifies adaptive aneuploidy as a mechanism of fluconazole resistance in Candida auris. Antimicrob Agents Chemother. 2020;65(1):e01466-20. https://doi.org/10.1128/AAC.01466-20
42. Barough R, Abastabar M, Moazeni M, et al. Deciphering fluconazole resistance in Candida auris clade V: the role of efflux pump gene expression and ergosterol pathway mutations. Mycopathologia. 2025;190(3):38. https://doi.org/10.1007/s11046-025-00945-7
43. Zhang C, Liu J, Jiang Y, Sun S. Nanotechnology-driven synergy: effects of curcumin nanosuspension and fluconazole combination in overcoming azole resistance in Candida albicans. Microbiol Spectr. 2025;13(12):e01520-25. https://doi.org/10.1128/spectrum.01520-25
44. Domingues Bianchin M, Borowicz SM, da Rosa Monte Machado G, et al. Lipid core nanoparticles as a broad strategy to reverse fluconazole resistance in multiple Candida species. Colloids Surf B Biointerfaces. 2019;175:523–529. https://doi.org/10.1016/j.colsurfb.2018.12.011
45. Woods M, Bermas A, Ball B, et al. Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans. Nat Commun. 2025;16(1):6248. https://doi.org/10.1038/s41467-025-61412-x
46. Gutierrez-Gongora D, Woods M, Prosser RS, Geddes-McAlister J. Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in Cryptococcus neoformans. Microbiol Spectr. 2024;12(3):e0284123. https://doi.org/10.1128/spectrum.02841-23
47. Alabi PE, Gautier C, Murphy TP, et al. Small molecules restore azole activity against drug-tolerant and drug-resistant Candida isolates. mBio. 2023;14(4):e0047923. https://doi.org/10.1128/mbio.00479-23
48. Daneshnia F, de Almeida Júnior JN, Ilkit M, et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. Lancet Microbe. 2023;4(6):e470–e480. https://doi.org/10.1016/S2666-5247(23)00067-8

Cite this article as:
Varfa N. A Comprehensive Review on Fluconazole: Clinical Efficacy, Pharmacokinetics, and Newly Emerging Challenges of Resistance. Premier Journal of Science 2026;23:100276

Export to EndNote Export to Mendeley